On the eve of Pfizer Inc.’sdeadline for bids for its consumer health business, the firm gave no indication whether it will follow through on potentially selling the division. Most analysts are recommending a spin-off.
During Pfizer's 2017 fourth-quarter and full-year earnings briefing on Jan. 30, CEO Ian Read said "strategic options" for the business...







